Abstract：
OBJECTIVE: The aim of this study was to examine particular single-nucleotide polymorphisms (IL-1A-889 C/T - rs1800587, IL-1B +3953 C/T - rs 1143634) of interleukins 1A and 1B in the development and prognosis of medication-related osteonecrosis of the jaw.
METHODS: DentiGen Parodontitis Tests were applied for collecting samples. This test is suitable for sampling oral mucosa cells in order to detect interleukins 1A and 1B single nucleotide polymorphisms (IL-1A-889, IL-1B+3953). Genetic samples were evaluated in the Istenhegyi Genediagnostic Center using the DNA-hybridization method. Genetic samples were collected in the patient group and the control group. The role of gene polymorphisms in the development of the disease was investigated by comparing the genetic results for the patient and control groups. The investigation of gene polymorphisms in disease prognosis is based on stage improvement, recovery, and relapses following treatment.
RESULTS: In total, 91 patients with MRONJ and 59 healthy controls were included in the study. 51 patients in the patient group and 37 controls had unfavorable allelic variants. No association (Mp = 1.42, SDp = 0.496, Mc = 1.35, SDc = 0.482, p = 0.52) was found between unfavorable polymorphisms and the development of the MRONJ. In the patient group, surgical therapy was required in 79 cases. Stage improvement was detected in 78 cases, recovery in 67 cases, and relapse in 33 cases. No stage improvement was found in one case, recovery in nine cases, or relapse in 34 cases. Of the 79 patients requiring surgical therapy, 49 had unfavorable allelic variants. No connection was found between the polymorphisms examined and stage improvement (Mp = 1.37, SDp = 0.486, Mnp = 2, SDnp = -, p = 0.800) or recovery (Mp = 1.39, SDp = 0.491, Mnp = 1.44, SDnp = 0.527, p = 0.990). However, a significant association (Mp = 1.21, SDp = 0.415, Mnp = 1.58, SDnp = 0.502, p < 0.001) was found between relapses and the presence of unfavorable allelic variants.
CONCLUSIONS: Within the possible limitations of this study, it can be assumed that the analysis of certain single-nucleotide polymorphisms of interleukin-1 may have the potential to help define the risk stratification of MRONJ after surgical therapy.
METHODS: DentiGen Parodontitis Tests were applied for collecting samples. This test is suitable for sampling oral mucosa cells in order to detect interleukins 1A and 1B single nucleotide polymorphisms (IL-1A-889, IL-1B+3953). Genetic samples were evaluated in the Istenhegyi Genediagnostic Center using the DNA-hybridization method. Genetic samples were collected in the patient group and the control group. The role of gene polymorphisms in the development of the disease was investigated by comparing the genetic results for the patient and control groups. The investigation of gene polymorphisms in disease prognosis is based on stage improvement, recovery, and relapses following treatment.
RESULTS: In total, 91 patients with MRONJ and 59 healthy controls were included in the study. 51 patients in the patient group and 37 controls had unfavorable allelic variants. No association (Mp = 1.42, SDp = 0.496, Mc = 1.35, SDc = 0.482, p = 0.52) was found between unfavorable polymorphisms and the development of the MRONJ. In the patient group, surgical therapy was required in 79 cases. Stage improvement was detected in 78 cases, recovery in 67 cases, and relapse in 33 cases. No stage improvement was found in one case, recovery in nine cases, or relapse in 34 cases. Of the 79 patients requiring surgical therapy, 49 had unfavorable allelic variants. No connection was found between the polymorphisms examined and stage improvement (Mp = 1.37, SDp = 0.486, Mnp = 2, SDnp = -, p = 0.800) or recovery (Mp = 1.39, SDp = 0.491, Mnp = 1.44, SDnp = 0.527, p = 0.990). However, a significant association (Mp = 1.21, SDp = 0.415, Mnp = 1.58, SDnp = 0.502, p < 0.001) was found between relapses and the presence of unfavorable allelic variants.
CONCLUSIONS: Within the possible limitations of this study, it can be assumed that the analysis of certain single-nucleotide polymorphisms of interleukin-1 may have the potential to help define the risk stratification of MRONJ after surgical therapy.
摘要：
目的：这项研究的目的是检查白介素1A和1B的特定单核苷酸多态性（IL-1A-889C/T-rs1800587，IL-1B3953C/T-rs1143634）在药物相关的颌骨坏死的发展和预后中的作用。
方法：牙本质牙周炎试验用于收集样本。本试验适用于对口腔粘膜细胞取样,以检测白细胞介素1A和1B单核苷酸多态性(IL-1A-889,IL-1B+3953)。使用DNA杂交方法在Istenhegyi基因诊断中心评估遗传样品。在患者组和对照组中收集遗传样本。通过比较患者和对照组的遗传结果，研究了基因多态性在疾病发展中的作用。基因多态性在疾病预后中的研究基于阶段改善，recovery,治疗后复发。
结果：总计，91名MRONJ患者和59名健康对照者被纳入研究。患者组中的51名患者和37名对照具有不利的等位基因变异。在不利的多态性与MRONJ的发展之间没有发现关联（Mp=1.42，SDp=0.496，Mc=1.35，SDc=0.482，p=0.52）。在病人组中,79例需要手术治疗。在78例中发现了阶段改善，67例复苏，33例复发。在一个案例中没有发现阶段改善，九例复苏，或复发34例。在79名需要手术治疗的患者中，49具有不利的等位基因变体。在检测的多态性和阶段改善之间没有发现联系（Mp=1.37，SDp=0.486，Mnp=2，SDnp=-，p=0.800）或回收率（Mp=1.39，SDp=0.491，Mnp=1.44，SDnp=0.527，p=0.990）。然而,在复发和存在不利的等位基因变异体之间发现了显著关联(Mp=1.21,SDp=0.415,Mnp=1.58,SDnp=0.502,p<0.001).
结论：在本研究的可能限制范围内，可以假设,对白细胞介素-1某些单核苷酸多态性的分析可能有助于确定手术治疗后MRONJ的风险分层.
方法：牙本质牙周炎试验用于收集样本。本试验适用于对口腔粘膜细胞取样,以检测白细胞介素1A和1B单核苷酸多态性(IL-1A-889,IL-1B+3953)。使用DNA杂交方法在Istenhegyi基因诊断中心评估遗传样品。在患者组和对照组中收集遗传样本。通过比较患者和对照组的遗传结果，研究了基因多态性在疾病发展中的作用。基因多态性在疾病预后中的研究基于阶段改善，recovery,治疗后复发。
结果：总计，91名MRONJ患者和59名健康对照者被纳入研究。患者组中的51名患者和37名对照具有不利的等位基因变异。在不利的多态性与MRONJ的发展之间没有发现关联（Mp=1.42，SDp=0.496，Mc=1.35，SDc=0.482，p=0.52）。在病人组中,79例需要手术治疗。在78例中发现了阶段改善，67例复苏，33例复发。在一个案例中没有发现阶段改善，九例复苏，或复发34例。在79名需要手术治疗的患者中，49具有不利的等位基因变体。在检测的多态性和阶段改善之间没有发现联系（Mp=1.37，SDp=0.486，Mnp=2，SDnp=-，p=0.800）或回收率（Mp=1.39，SDp=0.491，Mnp=1.44，SDnp=0.527，p=0.990）。然而,在复发和存在不利的等位基因变异体之间发现了显著关联(Mp=1.21,SDp=0.415,Mnp=1.58,SDnp=0.502,p<0.001).
结论：在本研究的可能限制范围内，可以假设,对白细胞介素-1某些单核苷酸多态性的分析可能有助于确定手术治疗后MRONJ的风险分层.
